Swiss drugmaker Novartis's logo at the company's plant in Stein, Switzerland. Picture: REUTERS/ARND WIEGMANN
The drug was approved to treat secondary progressive multiple sclerosis, which afflicts about 100,000 people in the US, said Paul Hudson, head of the Basel, Switzerland-based company’s pharmaceutical business. An additional 150,000 patients might also be candidates for the therapy, as eight out of 10 of people with the more common type of multiple sclerosis, known as relapsing-remitting, will see their disease worsen into the severe form, he said Wednesday.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: